Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.65 |
| ▸ | MAOB | P27338 | 4/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | RORA | P35398 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | RORB | Q92753 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL28599047 | 0.96 | MAOA (0.60) | MAOAMAOBACHECYP2D6PGR | |
| Trimethylammonium SCHEMBL28596346 | 0.96 | CYP2D6 (0.63) | MAOAMAOBACHECYP2D6PGR | |
| SCHEMBL17102952 | 0.95 | MAOA (0.68) | MAOAMAOBACHECYP2D6PGR | |
| SCHEMBL17102956 | 0.94 | MAOA (0.70) | MAOAMAOBACHECYP2D6PGR | |
| SCHEMBL8162588 | 0.94 | MAOA (0.70) | MAOAMAOBACHECYP2D6PGR | |
| SCHEMBL8173126 | 0.94 | MAOA (0.70) | MAOAMAOBACHECYP2D6PGR | |
| SCHEMBL17102941 | 0.94 | MAOA (0.70) | MAOAMAOBACHECYP2D6PGR | |
| SCHEMBL2721051 | 0.90 | MAOA (0.59) | MAOAMAOBACHECYP2D6PGR | |
| SCHEMBL17502355 | 0.90 | MAOA (0.78) | MAOAMAOBACHECYP2D6HDAC6 | |
| SCHEMBL17517489 | 0.89 | MAOA (0.81) | MAOAMAOBACHECYP2D6HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2924042-A1 | BIS- -CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2015-09-30 | — | — | EP | disclosed |
| CN-104755078-A | Application of harmine derivatives in preparation of antimicrobial agents | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD | 2015-07-01 | — | — | CN | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| CN-103070862-A | Application of harmine derivative in preparation of antibacterial drugs | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD | 2013-05-01 | — | — | CN | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SNCA, CHAT | MAOA 130/4885MAOB 48/4885ACHE 23/4885 |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | MAOA 48/4885MAOB 16/4885ACHE 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.